CGEN
CGEN
NASDAQ · Biotechnology

Compugen Ltd

$2.12
+0.03 (+1.44%)
Financial Highlights (FY 2026)
Revenue
35.98M
Net Income
35.50M
Gross Margin
94.0%
Profit Margin
-56.1%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 94.0% 67.8% 67.8% 67.8%
Operating Margin -38.8% 23.0% 25.1% 22.8%
Profit Margin -56.1% 19.8% 24.2% 26.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 35.98M 14.58M 13.34M 13.91M
Gross Profit 33.82M 9.89M 9.05M 9.44M
Operating Income -13,970,928 3.36M 3.34M 3.17M
Net Income 35.50M 2.88M 3.22M 3.61M
Gross Margin 94.0% 67.8% 67.8% 67.8%
Operating Margin -38.8% 23.0% 25.1% 22.8%
Profit Margin -56.1% 19.8% 24.2% 26.0%
Rev Growth — -8.4% -7.1% -8.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 49.00M 44.00M 47.56M
Total Equity — 75.78M 75.57M 70.88M
D/E Ratio — 0.65 0.58 0.67
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 31.95M 4.55M 4.43M 4.67M
Free Cash Flow — 4.06M 3.77M 3.36M